CDMOP News and Press, Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock From 03/08/21

Avid Bioservices, Inc. (CDMO) Q3 2021 Earnings Conference Call March 8, 2021 16:30 ET Company Participants Tim Brons - Investor Relations, Vida Strategic Partners Nick Green - President & Chief Executive Officer Dan Hart - Chief Financial Officer Timothy Compton - Chief Commercial Officer...

TUSTIN, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and m...

-- Third Quarter Revenue Increased 61% to $21.8 Million -- -- S igned $74 Million in New Orders to End the Quarter with a Backlog of $120 Million -- -- First Phase of Myford Expansion on Target, Accelerated Start of Second Phase -- -- Raised Gross Pro...

Avid Bioservices Cum Conv Red Perp Pfd Registered Series E (CDMOP) declares $0.6563/share quarterly dividend, in line with previous.Forward yield 8.47%Payable April 1; for shareholders of record March 15; ex-div March 12.See CDMOP Dividend Scorecard, Yield Chart, & Dividend Growth. For ...

TUSTIN, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biote...

Build Out of Myford Facility Will Expand Current Footprint to Include Second Manufacturing Train with Both Upstream and Downstream Processing Suites Phase 2 Has Potential to Increase Annual Revenue Generating Capacity by an Additional $100 Million TUSTIN, Calif., Feb. 22, 20...

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab ™ , Humanig...

BURLINGAME, Calif. and TUSTIN, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered into a manufacturing services agr...

TUSTIN, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotec...

TUSTIN, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotec...